# reload+after+2024-01-23 12:46:10.967933
address1§60 rue de Wattignies
city§Paris
zip§75012
country§France
phone§33 1 40 26 04 70
fax§33 1 40 26 04 44
website§https://www.nanobiotix.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. Nanobiotix S.A. has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is headquartered in Paris, France.
fullTimeEmployees§101
companyOfficers§[{'maxAge': 1, 'name': 'Mr. Laurent  Levy Ph.D.', 'age': 50, 'title': 'Co-Founder, President of the Executive Board & CEO', 'yearBorn': 1973, 'fiscalYear': 2022, 'totalPay': 695865, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Bart  Van Rhijn', 'age': 50, 'title': 'CFO & Member of Executive Board', 'yearBorn': 1973, 'fiscalYear': 2022, 'totalPay': 617309, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Anne-Juliette  Hermant M.A.', 'age': 49, 'title': 'Chief People Officer & Member of Executive Board', 'yearBorn': 1974, 'fiscalYear': 2022, 'totalPay': 339362, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Earl J. Bergey Ph.d.', 'age': 68, 'title': 'Co-Founder', 'yearBorn': 1955, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Alain  Dostie', 'title': 'Chief Operating Officer', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Craig  West CFA', 'title': 'Senior Vice President of Investor Relations', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Brandon  Owens', 'title': 'VP of Strategic Marketing & Corporate Communication', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Patrick  Tricoli M.B.A., Pharm.D.', 'title': 'Global Head of Business Development', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Margaret  Galluzzi', 'title': 'VP & Global Head of Clinical Operations', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Ventzislav  Vassilev M.D.', 'title': 'VP & Global Head of Safety Vigilance', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
auditRisk§9
boardRisk§7
compensationRisk§10
shareHolderRightsRisk§7
overallRisk§8
governanceEpochDate§1704067200
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§2
payoutRatio§0.0
beta§1.219
priceToSalesTrailing12Months§53.915703
currency§USD
dateShortInterest§1702598400
forwardEps§-2.52
exchange§NMS
quoteType§EQUITY
shortName§Nanobiotix S.A.
longName§Nanobiotix S.A.
firstTradeDateEpochUtc§1607697000
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§eaa89785-6330-34d6-a007-8a168e42ba35
gmtOffSetMilliseconds§-18000000
targetHighPrice§12.94
targetLowPrice§11.03
targetMeanPrice§12.13
targetMedianPrice§12.4
recommendationMean§1.3
recommendationKey§strong_buy
numberOfAnalystOpinions§3
quickRatio§0.602
grossMargins§1.0
ebitdaMargins§0.0
trailingPegRatio§None
